Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 6/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.39 |
| ▸ | MET | P08581 | 2/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | INSR | P06213 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12404986 | 0.93 | EGFR (0.51) | EGFRBTKKEAP1NFE2L2MAPT | |
| SCHEMBL6172239 | 0.83 | LMNA (0.42) | EGFRBTKKEAP1NFE2L2MAPT | |
| SCHEMBL29620812 | 0.83 | LMNA (0.42) | EGFRBTKKEAP1NFE2L2MAPT | |
| SCHEMBL12405419 | 0.83 | EGFR (0.49) | EGFRBTKKEAP1NFE2L2MAPT | |
| SCHEMBL6183885 | 0.82 | EGFR (0.41) | EGFRBTKKEAP1NFE2L2MAPT | |
| SCHEMBL12404957 | 0.82 | EGFR (0.52) | EGFRBTKKEAP1NFE2L2MAPT | |
| SCHEMBL12405352 | 0.81 | EGFR (0.53) | EGFRBTKKEAP1NFE2L2MAPT | |
| SCHEMBL13387507 | 0.81 | EGFR (0.49) | EGFRBTKKEAP1NFE2L2MAPT | |
| SCHEMBL12404982 | 0.81 | EGFR (0.51) | EGFRBTKKEAP1NFE2L2MAPT | |
| SCHEMBL3132755 | 0.80 | NOTUM (0.54) | MAPTTHRBUSP30KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985748-B2 | ALPHA2C adrenoreceptor agonists | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2011-07-26 | — | — | US | disclosed |
| US-7985748-B2 | ALPHA2C adrenoreceptor agonists | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2011-07-26 | — | — | US | disclosed |
| EP-1934203-B1 | 3,4-dihydro-2H-benzo[1,4]oxazine and 3,4-dihydro-2H-benzo[1,4]thiazine COMPOUNDS AS ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORP (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20100173823-A1 | ALPHA2C ADRENORECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. | 2010-07-08 | — | — | US | disclosed |
| US-20100173823-A1 | ALPHA2C ADRENORECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. | 2010-07-08 | — | — | US | disclosed |
| US-7700592-B2 | α2C adrenoreceptor agonists | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700592-B2 | α2C adrenoreceptor agonists | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| WO-2008100463-A1 | 3,4-DIHYDR0-L,4-BENZ0XAZINE, 3, 4-DIHYDR0-1, 4-BENZOTHIAZINE AND 1,2,3,4-TETRAHYDRO-QUINOXALINE DERIVATIVES AS ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2008-08-21 | — | — | WO | disclosed |
| US-20080039439-A1 | Alpha2C adrenoreceptor agonists | SCHERING CORPORATION | 2008-02-14 | — | — | US | disclosed |
| US-20080039439-A1 | Alpha2C adrenoreceptor agonists | SCHERING CORPORATION | 2008-02-14 | — | — | US | disclosed |
| US-20070093477-A1 | Alpha2C adrenoreceptor agonists | SCHERING CORPORATION AND PHARMACOPEIA DRUG DISCOVERY, INC. | 2007-04-26 | — | — | US | disclosed |
| US-20070093477-A1 | Alpha2C adrenoreceptor agonists | SCHERING CORPORATION AND PHARMACOPEIA DRUG DISCOVERY, INC. | 2007-04-26 | — | — | US | disclosed |
| WO-2007024949-A2 | ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173823-A1 | ALPHA2C ADRENORECEPTOR AGONISTS | ADRA2C, ADRB2, ADRA2A | EGFR 4346/4885BTK 4199/4885KEAP1 987/4885 |
| US-20070093477-A1 | Alpha2C adrenoreceptor agonists | ADRA2C, ADRB2, ADRA2A | EGFR 4346/4885BTK 4199/4885KEAP1 987/4885 |
| US-20080039439-A1 | Alpha2C adrenoreceptor agonists | ADRA2C, ADRB2, ADRA2A | EGFR 4346/4885BTK 4199/4885KEAP1 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.